MSD

<a href="https://www.bioagilytix.com/blog/category/cytokine-analysis/">Cytokine Analysis</a>

Multiplexed Cytokine Analysis in Drug Development

  • October 31, 2022

Cytokines are proteins released by activated cells that serve as soluble messengers binding to target cells through surface receptors, signaling functional responses. The nature of…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/cell-based-assays/">Cell-Based Assays</a>

The Importance of Cytokine Detection and Analysis

  • December 2, 2020

Cytokines are a broad class of soluble proteins, glycoproteins, and peptides that act as chemical messengers of the immune system. These small proteins are essential…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/bioagilytix-insight/">BioAgilytix Insight</a>

Bioanalytical Testing Under GMP: Assuring Biologic Safety & Efficacy via Impurities Assays

  • February 6, 2020

We discuss the need to put phase-appropriate methods in place to identify and quantify both process- and host-cell related impurities throughout the drug development process.

Find Out More
<a href="https://www.bioagilytix.com/blog/category/biomarkers/">Biomarkers</a>

C-Path “Points to Consider Document” Clarifies Bioanalytical Assay Validation in Support of Clinical Biomarker Qualification

  • August 13, 2019

A contributing author to the Critical Path Institute (C-Path)’s “Points to Consider Document,” Dr. Afshin Safavi summarizes considerations outlined in the paper designed to establish…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/bioagilytix-insight/">BioAgilytix Insight</a>

510K Approved Assays vs. RUO Assays: Which Best Support Clinical Trial Biomarker Studies?

  • July 11, 2019

The answer to the question is “it depends”. Commonly a combination of 510K approved kits (in Europe known as assays that need to follow IVD-directive…

Find Out More